CNBX Patent Application "Composition and Method for Treating Cancer with Cannabinoids" Enters National Phase in US and Israel

News provided by

CNBX Pharmaceuticals Inc.

13 Oct, 2022, 15:55 IDT

REHOVOT, Israel and BETHESDA, Md., Oct. 13, 2022 /PRNewswire/ - CNBX Pharmaceuticals Inc. (OTC-QB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that the Company's patent application titled "COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS" was filed on October 12, 2022 with the US Patent and Trademark Office (USPTO) and with the Israel Patent Office under a national phase of International Patent Application. National phase filing in Europe will follow.

Said patent application relates to several of the drug candidates on the Company's pipeline for the treatment of various types of cancer, including CNBX RCC-33, for the treatment of colorectal cancer currently being developed and prepared for a pre-IND meeting with the FDA and a first-in-human Phase I/II(a) validation study.

The company's growing IP portfolio includes 8 patent families, with 7 granted patents and 18 additional pending. The company's IP portfolio is focused on cancer patients and cancer treatments, and includes claims relating to Pharmaceutical Compositions, Methods and Systems.

Recent News:

About CNBX Pharmaceuticals:

CNBX Pharmaceuticals Inc. (OTC-QB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cnbxpharma.com. For the latest updates on CNBX Pharmaceuticals follow the Company on Twitter@cnbxpharma, Facebook@cnbxPharmaceuticals, LinkedIn https://www.linkedin.com/company/cnbx, and on Instagram @CNBX_Pharmaceuticals.

Disclaimer:

Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2022. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.

For more information about CNBX:

CNBX Pharmaceuticals Inc.
+1 (877) 424-2429
[email protected]
https://www.cnbxpharma.com

Logo: https://mma.prnewswire.com/media/1774404/CNBX_Pharmaceuticals_Logo.jpg

SOURCE CNBX Pharmaceuticals Inc.